Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with news of another biotech megaround, the potential next big thing from Novo Nordisk, and an anti-aging dispute involving dogs.
VC megarounds still happen
Alumis, a San Francisco biotech firm, has raised $259 million in venture capital to advance its oral anti-inflammatory, bucking some dismal trends in recent fundraising.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe
